Introduction The aim of this study was to report 36-month longitudinal changes using the North Star Ambulatory Assessment (NSAA) in ambulant patients affected by Duchenne muscular dystrophy amenable to skip exons 44, 45, 51 or 53. Materials and methods We included 101 patients, 34 had deletions amenable to skip exon 44, 25 exon 45, 19 exon 51, and 28 exon 53, not recruited in any ongoing clinical trials. Five patients were counted to skip exon 51 and 53 since they had a single deletion of exon 52. Results The difference between subgroups (skip 44, 45, 51 and 53) was significant at 12 (p = 0.043), 24 (p = 0.005) and 36 months (p≤0.001). Discussion Mutations amenable to skip exons 53 and 51 had lower baseline values and more negative changes ...
Novel emerging therapies for Duchenne muscular dystrophy (DMD), such as antisense oligomer (AO) medi...
Objective In the last few years some of the therapeutical approaches for Duchenne muscular dystro...
International audienceBackground: Exon skipping therapy is an emerging approach in Duchenne Muscular...
IntroductionThe aim of this study was to report 36-month longitudinal changes using the North Star A...
IntroductionThe aim of this international collaborative effort was to report 36-month longitudinal c...
Introduction The aim of this study was to report 36-month longitudinal changes using the North Star ...
Introduction The aim of this international collaborative effort was to report 36-month longitudinal ...
Abstract. Duchenne muscular dystrophy has a severe disease course, though variability exists. Case r...
Antisense oligonucleotide (AON)-mediated exon skipping is an emerging therapeutic for individuals wi...
Objective:To correlate time to loss of ambulation (LoA) and different truncating DMD gene mutations ...
In the last few years some of the therapeutical approaches for Duchenne muscular dystrophy (DMD) are...
Background: Exon skipping therapy is an emerging approach in Duchenne Muscular Dystrophy (DMD). Anti...
Novel emerging therapies for Duchenne muscular dystrophy (DMD), such as antisense oligomer (AO) medi...
Objective In the last few years some of the therapeutical approaches for Duchenne muscular dystro...
International audienceBackground: Exon skipping therapy is an emerging approach in Duchenne Muscular...
IntroductionThe aim of this study was to report 36-month longitudinal changes using the North Star A...
IntroductionThe aim of this international collaborative effort was to report 36-month longitudinal c...
Introduction The aim of this study was to report 36-month longitudinal changes using the North Star ...
Introduction The aim of this international collaborative effort was to report 36-month longitudinal ...
Abstract. Duchenne muscular dystrophy has a severe disease course, though variability exists. Case r...
Antisense oligonucleotide (AON)-mediated exon skipping is an emerging therapeutic for individuals wi...
Objective:To correlate time to loss of ambulation (LoA) and different truncating DMD gene mutations ...
In the last few years some of the therapeutical approaches for Duchenne muscular dystrophy (DMD) are...
Background: Exon skipping therapy is an emerging approach in Duchenne Muscular Dystrophy (DMD). Anti...
Novel emerging therapies for Duchenne muscular dystrophy (DMD), such as antisense oligomer (AO) medi...
Objective In the last few years some of the therapeutical approaches for Duchenne muscular dystro...
International audienceBackground: Exon skipping therapy is an emerging approach in Duchenne Muscular...